← Patent-cliff monitor small molecule MEKTOVI BINIMETINIB
Loss of exclusivity October 2033 latest FDA-listed patent expiry
Drug detail Brand name MEKTOVI Active ingredient BINIMETINIB Strength 15MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval June 2018 Marketing status RX
Listed patents Patent Expires Type 9598376 October 2033 use U-2330 9562016 October 2033 substance, product 9980944 October 2033 use U-2334 9314464 July 2031 use U-3737 9850229 August 2030 use U-2333 10005761 August 2030 use U-3737 7777050 March 2027 substance, product
Regulatory exclusivity Code Expires I-928 October 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.